|
Results of General Meeting
|
30 June 2023 at 1:00pm
|
|
Trading Halt
|
30 June 2023 at 10:15am
|
|
General Meeting - Chairman Script
|
30 June 2023 at 10:10am
|
|
Motor Neurone Disease Phase 1/2 Clinical Trial Update
|
27 June 2023 at 8:40am
|
|
Commencement of Cohort 3 in Phase 1/2 MND Trial
|
9 June 2023 at 10:15am
|
|
PharmAust MND Trial Interim Analysis PK Outcomes
|
7 June 2023 at 10:00am
|
|
Trading Halt
|
5 June 2023 at 10:05am
|
|
Notice of General Meeting/Proxy Form
|
26 May 2023 at 1:40pm
|
|
Motor Neurone Disease Clinical Trial Update
|
22 May 2023 at 9:55am
|
|
Securities issued under LR7.1 & LR7.1A
|
16 May 2023 at 12:10pm
|
|
Progress update on Phase 1/2 MND interim analysis
|
16 May 2023 at 8:55am
|
|
Application for quotation of securities - PAA
|
11 May 2023 at 3:50pm
|
|
Cancel - Notification regarding unquoted securities - PAA
|
11 May 2023 at 3:50pm
|
|
Notification regarding unquoted securities - PAA
|
11 May 2023 at 9:55am
|
|
Terms & Conditions of Unlisted Options
|
11 May 2023 at 9:50am
|
|
Appendix 3Y
|
11 May 2023 at 9:45am
|
|
Section 708(5) Notice
|
11 May 2023 at 9:45am
|
|
Notification regarding unquoted securities - PAA
|
11 May 2023 at 9:30am
|
|
Notification regarding unquoted securities - PAA
|
11 May 2023 at 9:15am
|
|
Application for quotation of securities - PAA
|
11 May 2023 at 9:10am
|
|
Independent tests show MPL retains long-term shelf-life
|
10 May 2023 at 8:45am
|
|
MPL has anti-cancer effects across multiple cancer types
|
9 May 2023 at 8:40am
|
|
Proposed issue of securities - PAA
|
3 May 2023 at 10:30am
|
|
PharmAust Raises $2.5m via Placement
|
3 May 2023 at 10:30am
|
|
Appendix 4C and Quarterly Update
|
28 April 2023 at 6:50pm
|
|
Trading Halt
|
28 April 2023 at 6:45pm
|
|
MND Trial Successfully Completes Second Patient Cohort
|
28 April 2023 at 8:55am
|
|
Canine Trial Update
|
21 April 2023 at 8:40am
|
|
Arrival of additional MPL tablets
|
17 April 2023 at 8:50am
|
|
PharmAust launches international CEO search
|
13 April 2023 at 8:50am
|
|
MND Trial Completes Enrolment of Cohort 2
|
30 March 2023 at 9:40am
|
|
Stable Patient in MND trial reaches 6-months on MPL
|
28 March 2023 at 9:50am
|
|
PharmAust Investor Webinar Presentation
|
16 March 2023 at 8:35am
|
|
AOG Energy Conference Presentation
|
15 March 2023 at 8:00pm
|
|
Investor Webinar
|
14 March 2023 at 11:00am
|
|
Correction to Appendix 3Y
|
13 March 2023 at 5:40pm
|
|
Change of Director's Interest Notice
|
13 March 2023 at 10:05am
|
|
Canine Cancer Trial Update
|
7 March 2023 at 8:40am
|
|
Interim analysis recommended in MND trial
|
2 March 2023 at 8:35am
|
|
European Patent relating to MPL Combinations in Cancer
|
28 February 2023 at 8:20am
|
|
Appendix 4D & Half Year Report
|
27 February 2023 at 4:35pm
|
|
First Patient of Cohort 2 Dosed in MND Trial
|
20 February 2023 at 8:30am
|
|
PharmAust canine trial update
|
10 February 2023 at 10:15am
|
|
Appendix 4C and Quarterly Update
|
30 January 2023 at 4:10pm
|
|
PharmAust Progresses to Elevated Doses in MND Patients
|
20 January 2023 at 8:45am
|
|
Change of Director's Interest Notice
|
10 January 2023 at 5:05pm
|
|
MND Trial Successfully Completes First Patient Cohort
|
6 January 2023 at 9:35am
|
|
PharmAust Canine Trial Update clarification
|
20 December 2022 at 1:25pm
|
|
PharmAust Canine Trial Update
|
20 December 2022 at 8:45am
|
|
PharmAust Receives R&D Tax Incentive Refund
|
12 December 2022 at 9:35am
|
PharmAust